Haeseon Lee

Haeseon Lee

Auto-generated profile, based on publicly available information

Haeseon Lee

Department of Pharmacotherapy, University of Utah College of Pharmacy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Therapeutic Advances in Hematology
Verified
Journal Article
Open access
JLJi Yeon Lee
Ji Yeon Lee
HLHaeseon Lee
Haeseon Lee
SKSiin Kim
Siin Kim
HSHae Sun Suh
Hae Sun Suh
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematological disease. The development of complement inhibitors such as eculizumab, ravulizumab, and pegcetacoplan has revolutionized the management of PNH, leading to improvements in overall survival and quality of life for patients. Objectives: This systematic review aims to provide comprehensive evidence of the efficacy of complement inhibitors in relation to treatment duration. Design: This is a systematic review and meta-analysis. Data sources and methods: A thorough literature search was conducted in MEDLINE, EMBASE, and the Cochrane Library up to 3 May 2022. We included all prospective interventional studies including single-arm trials. The primary outcomes of interest were lactate dehydrogenase (LDH) levels, hemoglobin (Hb) concentrations, transfusion avoidance, and Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) scores. Results: Our study included a total of 27 studies, comprising 5 randomized controlled trials and 11 single-arm trials, with a total of 912 patients with PNH. We stratified the studies according to treatment duration, based on the most frequently reported period of 26 weeks. Our analysis showed that treatment-naïve patients who received complement inhibitors had a pooled estimate of a decrease in LDH levels from baseline by −1462.0 U/L (95% CI: −1735.6 to −1188.5) for treatment ⩽26 weeks and −1696.5 U/L (95% CI: −2122.7 to −1270.2) for treatment >26 weeks. The mean Hb levels were increased by 1.4 g/dL (95% CI: 0.5–2.3) and 1.9 g/dL (95% CI: 0.7−3.1) in each group. Treatment with any complement inhibitor prevented the need for transfusion in at least 50% of patients with PNH in all treatment periods. Clinically meaningful improvements in FACIT-F were observed both before and after 26 weeks, with a pooled estimate of 6.8 (95% CI: 6.0−7.6) and 9.5 (95% CI: 7.0−12.0), respectively. Conclusion: Our findings suggest that complement inhibitors can result in positive treatment outcomes and sustained benefits for patients with PNH.

10 October 2025 in Journal of Medical Economics
Verified
Journal Article
Open access
HLHaeseon Lee
Haeseon Lee
JCJeong-Yeon Cho
Jeong-Yeon Cho
JVJeffrey Vietri
Jeffrey Vietri
EDEuan Dawson
Euan Dawson
NCNathorn Chaiyakunapruk
Nathorn Chaiyakunapruk
Aims This study aimed to evaluate the cost-effectiveness of newly developed higher-valent pneumococcal conjugate vaccines (PCVs)-including PCV15, PCV20, and PCV21-for adult populations through a systematic review and meta-analysis of economic evaluations (MAEE), providing pooled incremental net benefits (INBs) as a quantitative summary across studies.Methods Economic evaluation studies of PCV15, PCV20, or PCV21 were identified through database searches (PubMed, EMBASE, EconLit, Tufts CEA registry, HTA database, and NITAG resource center) through November 2024. INBs were calculated and pooled using a random-effects model, with positive INB indicating cost-effectiveness. Outcomes were stratified by population age (≥18, ≥50, and ≥60 years), perspective (healthcare and societal), and country income level. Sensitivity analyses assessed the impact of funding sources, imputed variance, and incomplete sensitivity analysis.Results Twenty-seven studies were included, with 14 comparisons eligible for meta-analysis. PCV20 was the most frequently studied vaccine. From a healthcare perspective, PCV20 was significantly cost-effective compared to PCV15 followed by PPSV23 (PCV15 + PPSV23) in ≥18 population (INB: 19.3; 95% CI: 14.2 to 24.4) and ≥60 population (44.3; 21.1 to 67.4). A similar trend was observed when compared against PPSV23 alone (269.3; 96.4 to 442.1 and 161.2; 3.5 to 318.9). Among ≥18 population, PCV20 showed favorable INBs compared to PCV13 + PPSV23 (241.7; -5.6 to 488.9; healthcare perspective) and (171.4; -44.2 to 386.9; societal perspective), and no vaccine (65.6; -35.7 to 167.0; healthcare perspective). Among ≥60 population, PCV20 was significantly cost-effective compared to PCV15 alone (37.5; 28.0 to 47.0), but not compared to no vaccine (-13.3; -122.0 to 95.5). PCV15 and PCV21 had few meta-analyzable comparisons.Conclusions Higher-valent PCVs appear cost-effective in most adult populations and settings, especially in high-income countries and from the healthcare perspective. This meta-analysis provides a rigorous quantitative synthesis to support vaccine policy decisions.

28 August 2025 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
HHHyun Jin Han
Hyun Jin Han
SJSemin Jang
Semin Jang
RDRyu Dahye
Ryu Dahye
HLHaeseon Lee
Haeseon Lee
JLJi Yeon Lee
Ji Yeon Lee
HSHae Sun Suh
Hae Sun Suh
The current standard-of-care prophylaxis for respiratory syncytial virus (RSV) is primarily administered to high-risk infant populations. We conducted a cost-effectiveness analysis to determine the economically justifiable price of nirsevimab compared with the standard of care in preventing medically attended RSV-associated lower respiratory tract infections from all infants and palivizumab-eligible children <2 years in South Korea. A month-age-specific static decision-tree model was used from a societal perspective, with a primary time horizon of one RSV season and an extended time horizon of three years. The model compared nirsevimab with standard of care prevention, which included palivizumab for eligible infants and children under two during the RSV season. The outcome measure was an incremental cost-effectiveness ratio (ICER) to suggest economically justifiable prices. The maximum economically justifiable price of nirsevimab was $527 at a 1 gross domestic product (GDP) per capita willingness-to-pay (WTP) threshold and $607 at a 1.5 GDP per capita WTP threshold per quality-adjusted life year (QALY) gain. The ICER was $33,071 per QALY at the price of $527 and $49,769 per QALY at $607 for the total population. Sensitivity analyses identified RSV epidemiology, nirsevimab effectiveness, and price as the key drivers of ICER variations. Probabilistic sensitivity analyses showed that nirsevimab was cost-effective at $527 in 55% of the simulations at the 1 GDP threshold and 54% at the 1.5 GDP threshold. Nirsevimab is estimated to be a cost-effective intervention for preventing RSV-associated lower respiratory tract infections within a universal immunization program for all infants and palivizumab-eligible children <2 years in South Korea.